First Berlin reiterates Buy on Pharming Group, maintains EUR 2.20 price target

Bitget2026/10/29 13:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

First Berlin Equity Research reiterated its Buy rating on Pharming Group on Oct. 29, 2026.
Analyst Simon Scholes maintained a 12-month price target of EUR 2.20, implying 102% upside.
Third-quarter 2026 Ruconest revenue reached USD 94 million, beating consensus of USD 82 million.
EBIT totaled USD 29.9 million, exceeding First Berlin's USD 26.8 million estimate.
Full-year 2026 revenue guidance narrowed to USD 380 million–USD 390 million from USD 375 million–USD 395 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News (Ref. ID: rc_27230) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

First Berlin reiterates Buy on Pharming Group, maintains EUR 2.20 price target

You may also like

Crypto prices